Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Epigenetic deregulation in myeloid malignancies.

Meldi KM, Figueroa ME.

Transl Res. 2015 Jan;165(1):102-14. doi: 10.1016/j.trsl.2014.04.012. Epub 2014 Apr 24. Review.

PMID:
24813528
2.

Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Leone G, D'Alò F, Zardo G, Voso MT, Nervi C.

Curr Med Chem. 2008;15(13):1274-87. Review.

3.

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

Lowder JN, Taverna P, Issa JP.

Epigenomics. 2015 Oct;7(7):1083-8. doi: 10.2217/epi.15.66. Epub 2015 Nov 6. No abstract available.

PMID:
26541345
4.

Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.

Khan H, Vale C, Bhagat T, Verma A.

Semin Hematol. 2013 Jan;50(1):16-37. doi: 10.1053/j.seminhematol.2013.01.001. Review.

PMID:
23507481
5.

Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.

Hou HA, Tien HF.

Expert Rev Hematol. 2016 May;9(5):447-69. doi: 10.1586/17474086.2016.1144469. Epub 2016 Feb 9. Review.

PMID:
26789100
6.

Epigenetic therapies in MDS and AML.

Griffiths EA, Gore SD.

Adv Exp Med Biol. 2013;754:253-83. doi: 10.1007/978-1-4419-9967-2_13. Review.

7.

Digging deep into "dirty" drugs - modulation of the methylation machinery.

Pleyer L, Greil R.

Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Review.

8.

Epigenetic regulators and their impact on therapy in acute myeloid leukemia.

Pastore F, Levine RL.

Haematologica. 2016 Mar;101(3):269-78. doi: 10.3324/haematol.2015.140822. Review.

9.

[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].

Daskalakis M, Blagitko-Dorfs N, Hackanson B, Lübbert M.

Pharm Unserer Zeit. 2010 May;39(3):217-27. doi: 10.1002/pauz.201000369. Review. German. No abstract available.

PMID:
20425776
10.
11.

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Stahl M, Gore SD, Vey N, Prebet T.

Expert Opin Investig Drugs. 2016;25(3):307-17. doi: 10.1517/13543784.2016.1146251. Review.

PMID:
26807602
12.

Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.

Jhanwar SC.

Adv Biol Regul. 2015 May;58:28-37. doi: 10.1016/j.jbior.2014.11.002. Epub 2014 Nov 20. Review.

PMID:
25499150
13.

Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.

Craddock C.

Cytotherapy. 2011 May;13(5):516-7. doi: 10.3109/14653249.2011.561652. Epub 2011 Mar 7. No abstract available.

PMID:
21375421
14.

Clinical development of demethylating agents in hematology.

Navada SC, Steinmann J, Lübbert M, Silverman LR.

J Clin Invest. 2014 Jan;124(1):40-6. doi: 10.1172/JCI69739. Epub 2014 Jan 2. Review.

15.

Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.

Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G.

Crit Rev Oncol Hematol. 2013 Nov;88(2):231-45. doi: 10.1016/j.critrevonc.2013.06.004. Epub 2013 Jul 7. Review.

PMID:
23838480
16.

The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.

Larsson CA, Cote G, Quintás-Cardama A.

Mol Cancer Res. 2013 Aug;11(8):815-27. doi: 10.1158/1541-7786.MCR-12-0695. Epub 2013 May 3. Review.

17.

Epigenetic changes in the myelodysplastic syndrome.

Issa JP.

Hematol Oncol Clin North Am. 2010 Apr;24(2):317-30. doi: 10.1016/j.hoc.2010.02.007. Review.

18.

Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.

Wong JJ, Lau KA, Pinello N, Rasko JE.

Cancer Sci. 2014 Nov;105(11):1457-63. doi: 10.1111/cas.12532. Epub 2014 Oct 18.

19.

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.

Voso MT, Lo-Coco F, Fianchi L.

Curr Opin Oncol. 2015 Nov;27(6):532-9. doi: 10.1097/CCO.0000000000000231. Review.

PMID:
26352541
20.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301

Supplemental Content

Support Center